Clinical and Translational Science Institute

Centers

12-26-2018

Capsule Integrated Polypeptide Multilayer Films for Effective pHResponsive Multiple Drug Co-Delivery
Shichao Zhang
West Virginia University

Malcolm Xing
Institute of Manitoba

Bingyun Li
West Virginia University

Follow this and additional works at: https://researchrepository.wvu.edu/ctsi
Part of the Medicine and Health Sciences Commons

Digital Commons Citation
Zhang, Shichao; Xing, Malcolm; and Li, Bingyun, "Capsule Integrated Polypeptide Multilayer Films for
Effective pH-Responsive Multiple Drug Co-Delivery" (2018). Clinical and Translational Science Institute.
31.
https://researchrepository.wvu.edu/ctsi/31

This Article is brought to you for free and open access by the Centers at The Research Repository @ WVU. It has
been accepted for inclusion in Clinical and Translational Science Institute by an authorized administrator of The
Research Repository @ WVU. For more information, please contact ian.harmon@mail.wvu.edu.

HHS Public Access
Author manuscript
Author Manuscript

ACS Appl Mater Interfaces. Author manuscript; available in PMC 2019 December 26.
Published in final edited form as:
ACS Appl Mater Interfaces. 2018 December 26; 10(51): 44267–44278. doi:10.1021/acsami.8b17264.

Capsule-Integrated Polypeptide Multilayer Films for Effective pHResponsive Multiple Drug Co-Delivery
Shichao Zhang†, Malcolm Xing‡, and Bingyun Li*,†
†Department

of Orthopaedics, School of Medicine, West Virginia University, Morgantown, West
Virginia 26506, United States

Author Manuscript

‡Department

of Mechanical Engineering, University of Manitoba, and The Children’s Hospital
Research Institute of Manitoba, Winnipeg, Manitoba R3E 3P4, Canada

Abstract
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Many applications using drug-carrying biomedical materials require on-demand, localized
delivery of multiple therapeutic agents in precisely controlled and patient-specific time sequences,
especially after assembly of the delivery vehicles; however, creating such materials has proven
extremely challenging. Here, we report a novel strategy to create polypeptide multilayer films
integrated with capsules as vehicles for co-delivery of multiple drugs using layer-by-layer selfassembly technology. Our approach allows the multilayered polypeptide nanofilms and
preimpregnated capsules to assemble into innovative biomedical materials with high and
controllable loading of multiple drugs at any time postpreparation and to achieve pH-responsive
and sustained release. The resulting capsule-integrated polypeptide multilayer films effectively codeliver various drugs with very different properties, including proteins (e.g., growth factors) and
nanoparticles, achieving bovine serum albumin loading of 80 μg cm−2 and release of 2 weeks, and
histone loading of 100 μg cm−2 and release of 6 weeks; which also enable Staphylococcus aureus
killing efficacy of 83% while maintaining osteoblast viability of >85% with silver nanoparticle
delivery; and >5-fold cell adhesion and proliferation capability with live cell percentage of >90%
via human recombinant bone morphogenetic protein 2 delivery. The successful development of
such fascinating materials can not only function as advanced nanocoatings to reduce two major
complications of orthopedic bone injuries (i.e., infection and delayed bone regeneration) but also
provide new insights into the design and development of multifunctional materials for various
other biomedical applications.
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1.

INTRODUCTION
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Biomedical implants, as a major component of modern medicine used to substitute missing
structure or function in the human body, play a critical role in various clinical applications
ranging from tissue repair and reconstruction, bone fracture fixation, hip and knee
replacement, and electronic sensory or monitoring to organ transplantation.1–4 However,
implant-associated infection and delayed tissue regeneration are two major clinical
complications, in particular for orthopedic implants, and can lead to poor functional
outcome, implant failure, additional surgery, and even death.5–7 To reduce these two
complications, the ideal implants should be designed to inhibit bacterial adhesion and
colonization and to induce appropriate cellular responses to promote osseointegration
without sacrificing the required structural and physicochemical properties and functions.8,9
Due to its integrated features of cost efficiency, localized release capacity, and ease of largescale synthesis, surface modification has been considered as one of the most promising
strategies to develop drug-delivery materials at the implant/ tissue interface to reduce
postoperative infections and to promote wound healing.10–13 However, the generation of
clinical nanomaterials with the capability to deliver drug molecules at the right place and
according to patients’ needs has been a major challenge and has attracted extensive attention
with the rapid development of nanotechnology.

Author Manuscript

Because of its integrated properties of flexible choice of assembly components, precise
control of assembly structure/ properties, and ease of processing on substrates (regardless of
size and shape), layer-by-layer (LbL) self-assembly has been known as a highly versatile
and facile nanomaterial assembly technique for modifying implants using drug-delivery
materials with controlled structures and functions.14–18 To date, a series of LbL-assembled
drug-delivery materials in the form of multilayer films and capsules have been prepared
from polyelectrolytes, amphiphilic polymers, hydrogels, micelles, etc.19–26 Despite the
localized and enhanced drug delivery, some drawbacks still remain for these assemblies. For
instance, most of these multilayer films carry only a single cargo or have limited loading
capacity, in which the drug is assembled as film components; they are still far from
satisfactory for most situations in which more than one therapeutic agent is needed.18,27–30
To enhance drug-loading capacity, hollow capsules have been designed and engineered via

ACS Appl Mater Interfaces. Author manuscript; available in PMC 2019 December 26.

Zhang et al.

Page 3

Author Manuscript

LbL self-assembly of shells on sacrificial templates, however, most of them barely meet the
requirements for clinical application due to limited structural controllability (like
incompleteness and aggregation), weak mechanical properties (easy to break during
implantation), and uncontrolled and unsustained release (burst release).31,32 Although some
multidrug delivery vehicles have been prepared and showed enhanced delivery capability,
they loaded drugs during the vehicle assembly process leading to loss of drug bioactivity,
limited drug variety (especially for drugs of different properties), and heavy burden on drug
storage in vehicles.33–36 Therefore, creating a strategy to develop delivery vehicles that can
achieve on-demand and localized release of multiple drugs in precisely controlled, patientspecific time sequences is still an ongoing challenge. Recently, polypeptide multilayer films
that can co-deliver gentamicin and bovine serum albumin (BSA) were first prepared in our
group and exhibited an enhanced multidrug loading capacity owing to our unique structural
design.22 This work provided an innovative preparation concept for drug delivery vehicles;
however, three challenges still remain: (i) only two model drugs of gentamicin and BSA
were used for proof of concept without the capability to resolve the two major complications
of implant-associated infection and delayed tissue regeneration, especially, no in vitro or in
vivo anti-infection and bone regeneration studies were conducted, (ii) the resultant films had
burst release of drugs and no means of controlling the burst release were examined, and (iii)
the loaded gentamicin may lead to antibiotic resistance, whereas BSA cannot function as a
therapeutic agent for bone regeneration.
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Here, we demonstrate a novel strategy for creating capsule-integrated polypeptide films as
vehicles to deliver multiple drugs with very different properties (e.g., opposite charges,
diverse monomers of molecule/particle) in postpreparation loading and pH-responsive and
sustained release manner for preventing implant-associated infections and promoting bone
regeneration. Microcapsules impregnated with polyelectrolytes function as primary delivery
vehicles with controllable drug binding capability; these microcapsules were designed and
evaluated in terms of morphology, structure, and delivery capacity. Moreover, the capsuleintegrated film vehicles were obtained by optimizing the loading of impregnated
polyelectrolytes in capsules and capsule density in polypeptide multilayer films. In addition,
the loading capacities and release profiles of four different drugs (BSA, calf thymus histone
H1, silver nanoparticles or AgNPs, and human recombinant bone morphogenetic protein 2
or rhBMP-2), in vivo mechanical properties, in vitro anti-infection capability against
Staphylococcus aureus, and in vitro bone regeneration capability of our resultant delivery
vehicles were conducted to demonstrate the robust application performance resulting from
sustained and precisely controlled multidrug delivery in patient-specific time sequences, to
resolve the two major complications (i.e., infection and delayed healing) of orthopedic bone
injuries.
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2.
2.1.

MATERIALS AND METHODS
Reagents and Materials.
Poly-L-lysine hydrobromide (PL, Mw 150–300 kDa), poly-L-glutamic acid sodium salt (PG,
Mw 50–100 kDa), PL labeled with fluorescein isothiocyanate (PL-FITC), sodium hydroxide
(≥97.0%), sodium chloride (≥99.5%), tris-(hydroxymethyl)aminomethane (≥99.8%),
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glutaraldehyde (GA), rhBMP-2, and rhBMP-2 enzyme-linked immunosorbent assay
(ELISA) kit were obtained from Sigma-Aldrich (St. Louis, MO). Simulated body fluid
(SBF) was prepared by dissolving reagent-grade salts in deionized water and had a
composition of 142.0 mM Na+, 5.0 mM K+, 1.5 mM Mg2+, 2.5 mM Ca2+, 4.2 mM HCO3-,
147.8 mM Cl-, 1.0 mM HPO42-, and 0.5 mM SO42-. Alexa Fluor 647-conjugated BSA,
Alexa Fluor 488-conjugated histone H1 from calf thymus, disodium
ethylenediaminetetraacetic acid (EDTA), and 0.25% trypsin/2.21 mM EDTA solution were
purchased from Thermo Fisher Scientific (Fair Lawn, NJ). Dulbecco’s modified Eagle’s
medium/nutrient mixture F-12 (DMEM/F-12) and penicillin/streptomycin (P/S) were
obtained from Life Technologies (Grand Island, NY). Fetal bovine serum (FBS) and
Dulbecco’s phosphate-buffered saline (PBS, pH 7.0) were purchased from Corning
(Manassas, VA). Tryptic soy broth (TSB) was obtained from Becton Dickinson (Sparks,
MD). AgNPs (diameter of ~10 nm) capped with poly(vinylpyrrolidone) (PVP) were
obtained from nanoComposix, Inc. (San Diego, CA). Calcium carbonate (CaCO3) particles
were purchased from PlasmaChem GmbH (Rudower Chaussee, Berlin, Germany). Stainless
steel Kirschner wires (K-wires) were purchased from Smith & Nephew, Inc. (Memphis,
TN). Quartz microscope slides (76.2 × 50.8 mm2) were bought from Electron Microscopy
Sciences (Hatfield, PA) and cleaned and cut into 10 × 25 mm2 for further use. N-type (100)
silicon wafers were supplied by Montco Silicon Technologies Inc. (Spring City, PA) and
cleaved into 10 × 25 mm2 rectangles for further use.
2.2. LbL Self-Assembly of Multilayer Nanofilms, Microcapsules, and Capsule-Integrated
Polypeptide Multilayer Films.

Author Manuscript

Polypeptide multilayer films were prepared using a dipping machine (Riegler and Kirstein
GmbH, Berlin, Germany). In brief, the precleaned substrates (i.e., quartz slides, steel disks,
silica wafers, and K-wires) were clamped on the dipping heads and immersed in PL solution
(positively charged) for 20 min, then rinsed with tris buffer solution for 3 min, and dried
with air. Next, the samples were coated using PG solution (negatively charged) with similar
dipping, rinsing, and drying processes. These two coating processes were referred to as one
coating cycle for one bilayer construction and can be repeated to deposit a multilayer film
with a well-defined structure and thickness.

Author Manuscript

To construct microcapsules for drug delivery, the polyelectrolytes (i.e., PL or PG) were
impregnated into CaCO3 particles via immersing them into 2 mg mL−1 PL or PG solution
for 30 min under vacuum pressure (3 Torr). The samples underwent a centrifugation to
remove the supernatant and were dried in a vacuum oven (380 Torr) at 60 °C overnight.
Polypeptides (i.e., PL and PG) were then alternatively used to construct the multilayer shells
on these preimpregnated particles using LbL self-assembly to form shelled CaCO3 particles,
in a similar manner as described above for coating on conventional substrates, however, in
this case, a centrifugation (3000 rpm for 1 min) step was added between the two coating
processes to make the coating processes on microparticles feasible. After that the shelled
CaCO3 particles were subjected to cross-linking by incubating them in a 25% GA solution
for 3 h to stabilize the multilayer shell. To form microcapsules, these shelled particles were
incubated in 0.1 M EDTA solution for 1 h, followed by centrifugation, and removal of
supernatants to dissolve the CaCO3 templates. Here, PL- and PG-impregnated CaCO3
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particles and their resultant capsules were designated as CaCO3PL, CaCO3PG, capsulePL, and
capsulePG, respectively.

Author Manuscript

The construction of capsule-integrated polypeptide multilayer films for multidrug delivery
was carried out by combining the LbL self-assembly processes of multilayer nanofilms and
microcapsules. The typical procedure is shown in Scheme 1: (1) self-assembly of (PL/ PG)x
multilayer nanofilms; (2) deposition of CaCO3PG particles; (3) self-assembly of PG/(PL/
PG)y multilayer nanofilms; (4) deposition of CaCO3PL particles; (5) self-assembly of
PG/(PL/PG)z multilayer nanofilms; and (6) formation of capsule-integrated multilayer films
by dissolving CaCO3 templates. In this work, the multilayer shells for CaCO3PL and
CaCO3PG particles were optimized as (PL/PG)3.5 films. The depositions of CaCO3PL or
CaCO3PG particles were achieved by dipping the nanofilms into 2 mL suspensions of shelled
particles (particle density of 6 × 10 mL−1) for a specific duration. The final capsuleintegrated polypeptide multilayer films were referred to as (PL/PG)x/capsulePG/PG/(PL/
PG)y/capsulePL/PG/(PL/PG)z, which was further simplified as Lx/CG/Ly/CL/Lz where L
represents PL/PG layers, CG and CL represent PG and PL-impregnated capsules,
respectively, and x, y, and z are the numbers of PL/PG bilayers.
2.3.

Drug Loading and Release.
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To load the drug models of fluorescently labeled BSA and histone, the multilayer films
(coated on 2 × 2 cm2 quartz slides) were incubated in 1 mg mL−1 of BSA or histone solution
(pH 7.4, PBS buffered) for various times. To load AgNP, the capsule-integrated multilayer
films were immersed into 0.1 mg mL−1 of AgNP suspension. rhBMP-2 loading was
conducted by incubating the capsule-integrated films in 4 μg mL−1 of rhBMP-2 solution (pH
7.4, PBS buffered). After incubating for a predetermined time period, the samples were
washed briefly in PBS to remove the loosely attached drug molecules or nanoparticles. The
loading of fluorescence-labeled drugs was confirmed using confocal laser scanning
microscopy (CLSM, LSM 510, Zeiss, Thornwood, NY), and their quantitative loading and
release were measured using a hybrid multimode microplate reader (Synergy H4, Winooski,
VT) as previously reported.9,37 In brief, the drug-loaded samples were sonicated in PBS, and
the amounts of encapsulated drugs or fluorescently labeled vehicles in the samples were
quantitatively determined. The drug-loading and encapsulation rate were calculated using
the following equations: (i) drug-loading rate = the amount of drug encapsulated in the
delivery vehicles/the total amount of delivery vehicles × 100% and (ii) encapsulation
efficiency = the amount of drug encapsulated in the delivery vehicles/the amount of drug in
the loading solution × 100%. The drug release measurements were conducted by incubating
the drug-loaded delivery vehicles in 2 mL of PBS or SBF (pH = 7.4) placed in a 37 °C water
bath on a rocker. At predetermined time periods, 400 μL of medium was taken to measure
the release of drugs, and 400 μL fresh PBS was added to keep the medium volume constant;
the cumulative drug release was calculated.
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2.4.

Cell Culture, Adhesion, and Proliferation.
A human osteoblast cell line CRL-11372 was supplied by American Type Cell Culture
(Manassas, VA) and cultured in 1:1 DMEM/F-12 medium supplemented with 10% FBS and
1% P/S in a T75 cell culture flask and incubated at 37 °C in a 5% CO2 atmosphere.
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Osteoblast cells were detached from the T75 flask using trypsin-EDTA solution and added
(cell density of 10 000 cell cm−2) into 24-well culture plates, in which the coated and
uncoated sterile quartz slides were placed. The culture medium was replaced every other
day. A clinical isolate of S. aureus (SA 1004) was obtained from Ruby Memorial Hospital
(Morgantown, WV) and stocked on sheep blood agar plates at 4 °C. Before using, S. aureus
was first cultured in TSB for 16 h at 37 °C and then diluted with fresh TSB and incubated at
37 °C for an additional 3 h to achieve log-phase growth. Different molar concentrations of
AgNPs and coated substrates with/without AgNP loading were added to 1 mL of inoculum
with a concentration of 1.0 × 105 colony forming units per milliliter (CFU mL−1) and
incubated for 24 h at 37 °C.
2.5.

Characterization.
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The morphologies of CaCO3 particles, microcapsules, PL/PG nanofilms, and capsuleintegrated films were characterized using S-4700 scanning electron microscope (SEM,
Hitachi Ltd., Japan) with an acceleration voltage of 5 kV after being coated with gold for
100 s and NanoScope atomic force microscopy (AFM, PicoSPM II, Tempe, AZ) operating
in a tapping mode. The thickness of multilayer films was examined using UV-vis
spectrometry (BioMate 3S, Thermo Electron Co., NY) and ellipsometry (M- 2000, JA
Woollam Co., Lincoln, NE). The water contact angle data (3 μL) were collected using
macrophotography of iPhone 7 plus and analyzed by Adobe Photoshop CS6 image analysis
software. The size distribution of AgNPs was collected with a Malvern NanoSight NS300
instrument using NTA Nanosight 3.2 software (Malvern Instruments, Westborough, MA),
whereas their ζ potential was measured using a Malvern Zetasizer Nano Z using Zetasizer
software (Malvern Instruments). To determine the S. aureus killing efficacy, the samples
from a 24-well culture plate were diluted (10−4, 10−5, and 10−6) in sterile PBS after various
treatments, plated on 5% sheep blood agar plates, and incubated for 24 h at 37 °C. The
numbers of CFUs were quantified, and the killing efficacy was calculated by dividing the
difference between the number of CFUs in the control and the number of CFUs in the
treated samples with the number of CFUs in the control and then multiplying by 100.
Osteoblast cell adhesion and proliferation were determined after detaching and counted
using a hemocytometer under a light microscope. Briefly, after culturing for a specific
duration, the substrates were removed from culture plates and rinsed with PBS three times.
Then, a typical trypsinization procedure, followed by centrifugation, was introduced to
detach cells on the substrates. After resuspending in PBS, the number of cells was counted
using a hemocytometer. Furthermore, the osteoblast viability assay was carried out using
trypan blue to count the number of viable cells. All data were presented as means ± standard
deviations. Comparisons between two groups were conducted using the Student’s t-test,
whereas comparisons between three groups or more were conducted with one-way analysis
of variance followed by Tukey’s honestly significant difference test. P-value < 0.05 was
considered statistically significant.
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RESULTS AND DISCUSSION
Structural Design and Analysis of Capsule- Integrated Multilayer Films.
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To create a drug-delivery system that can achieve high loading and on-demand and sustained
release of desired drugs requires a sophisticated structural design of delivery vehicles.38,39
We constructed our multidrug delivery vehicles via a hierarchical nano/microlevel design
based on three criteria: (l) the environment-responsive microcapsules must be assembled to
function as vehicles for multiple drugs of very different properties, (2) different capsules in
the constructed delivery system must be highly organized to achieve a sustained and
sequential release of desired drugs, and (3) the delivery vehicles can be assembled on any
required implants and used any time postpreparation. These three requirements are satisfied
by a facile and scalable strategy of the LbL self-assembly technique, which allows pHtriggered and impregnated microcapsules and PL/PG multilayer films to assemble into
highly integrated and organized delivery vehicles to effectively load and sequentially release
multiple drugs (e.g., AgNPs and rhBMP-2) to resolve two major complications of
orthopedic bone injuries (i.e., infection and delayed bone regeneration).
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Scheme 1 describes the synthesis pathway of our delivery vehicles of capsule-integrated
PL/PG multilayer films. Biocompatible polypeptide PL and PG were selected as the building
blocks to construct the delivery vehicles, and CaCO3 particles were used as templates to
assemble microcapsules. The as-prepared capsules were impregnated with PL or PG to
create pH-triggered loading and release capability for positively and negatively charged
drugs based on electrostatic interactions. To bring about further chemical bonding among PL
and PG molecules in capsules, the shelled CaCO3 particles were incubated using GA
solution to form cross-linked shells, endowing the resultant microcapsules with sufficient
stability without disassembly during template removal and drug loading. Moreover,
abundant aldehyde groups were also introduced due to the excessive GA during this crosslinking process, which allowed effective integrating interaction between microcapsules and
multilayer films.22 Besides the microcapsules, by carefully controlling PL/PG multilayer
films between different capsule layers, the sustained and precisely controlled release of
different drugs with designed sequence, dose, and duration, could be achieved for drug
delivery. Our capsule-integrated multilayer films were responsive to environmental pH. Such
behavior allows for the development of smart therapies for injured tissues, which usually
show varied pH values during the healing process, indicating a promising benefit in clinical
practice for broad medical applications.40–4 Using our previously reported open fracture rat
model,26 we measured the pH of tissue samples around infected and noninfected femurs l0
days after surgery, and their pH values were found to be approximately 7.0 and 6.5,
respectively (Figure Sl). The pH was relatively low at the infection site, which was
consistent with reports from other studies.43–45 Bacteria like Staphylococcus epidermidis or
S. aureus may create an acidic environment due to their metabolic production of acidic
substances like lactic acid,44 and local acidosis may occur due to massive infiltration of
neutrophils and macrophages recruited to the site of infection.45
We selected microsized and porous CaCO3 particles with diameter of ~6 μm to impregnate
with PL or PG polypeptides, which can function as active loading sites and to further
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assemble polypeptide shells for microcapsules. Figure 1a shows the typical CaCO3 particles,
on which abundant mesoporous pores were observed, meeting the requirements of rough
surface, large surface area, and high porosity for polyelectrolyte impregnation. Upon
incubating in 2 mg mL−1 of PL solution, the pore channels facilitated the penetration of
solution into CaCO3 particles due to capillary effect and led to the sufficient impregnation of
PL molecules, which adsorbed not only on particle surfaces but also in the interior, and thus
without being completely neutralized during subsequent LbL assembly.46 Therefore, these
excessive impregnated polyelectrolytes endowed the capsules with robust capacity to load
charged drugs. As expected, the pore size and surface roughness decreased obviously after
impregnation, further confirming the effective adhesion of PL polypeptides in CaCO3
particles, as shown in Figure 1b. Further using the LbL self-assembly technique, PL and PG
were alternatively deposited to form a shell of (PL/PG)3.5 onto CaCO3 particles, and the
cross-linked nanofilm-shelled particles are illustrated in Figure 1c. SEM examinations were
also conducted on dry shells after removal of CaCO3 templates and confirmed the formation
of microcapsules (Figure 1d). Figure 1e-g exhibits the typical formation process ranging
from PL/PG multilayer film and shelled particle-integrated film to capsule-integrated film,
revealing the successful hierarchical nano/microlevel self-assembly for our drug-delivery
vehicles. In addition, evidence of structural change due to incorporation of capsules was also
observed in AFM analyses (Figure 1h,i). The deposition of microcapsules led to an obvious
increase in surface roughness, indicating a desirable topography to enhance the cell-material
interactions for clinical applications.11,47,48
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To elaborate on the growth profile of PL/PG multilayer films, we measured the absorbance
of films on quartz slides using UV-vis spectrometry and the thickness of films on silicon
wafers using ellipsometry, as shown in Figure 2a,b. With an increasing number of PL/PG
bilayers, both the absorbance and thickness of multilayer films increased linearly, exhibiting
a steady self-assembly process of charged polypeptides regardless of substrates. The average
thickness of each bilayer was ~5.2 nm, which is consistent with our previous reports.26,49
Moreover, the growth profiles and stability of PL/PG multilayer films fabricated from
various solutions with different pH and sodium chloride (NaCl) contents were also studied,
and the results showed that higher pH and NaCl concentration in solutions facilitated the
assembly of polypeptide films; all assemblies exhibited good stability in PBS (Figure S2). In
light of the crucial role of surface wettability on competitive protein adsorption and initial
attachment of cells, we also investigated the correlation between hydrophilicity and the
outermost structure of PL/PG multilayer films. Figure 2c presents the change in WCAs of
films with different outermost layers. PL/ PG multilayer films with the outermost layer of
PL exhibited WCAs of 45–49°, whereas WCAs of the PG outermost layer were much
smaller and were within the range of 27–31° due to abundant side chain carboxyl groups of
PG. The WCAs of PL/PG multilayer films increased slightly with increasing bilayer
numbers, which could be attributed to the enhanced surface roughness according to the
Cassie model.50 A similar phenomenon was observed for the capsule-integrated (PL/ PG)3
multilayer films compared with (PL/PG)3 films, further confirming the dominant
contribution of microcapsules on the construction of hierarchical roughness of delivery
coatings.
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To evaluate the mechanical properties of our designed delivery vehicles, we prepared
capsule-integrated multilayer films on K-wires and tested their stability using our in vivo rat
model.51 The SEM result of the most severely damaged parts of the coating film on a K-wire
is illustrated in Figure 2d. After analyzing the thickness, regularity, and damage to the whole
films before and after implantation, we found that most damage occurred on the front part of
the coating on K-wires, which suffered the most abrasion during the drilling process into the
rat femur; more than 85% of the films withstood the implantation process in our in vivo rat
model. In addition, the long-term stability of the capsule-integrated polypeptide films in
solution was evaluated. As shown in Figures S3 and S4, no obvious changes were observed
in both film thickness and capsule structure after immersing the films in PBS for up to 10
days.
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We aimed to employ the microcapsules as the primary vehicles for drug delivery.
Consequently, our delivery vehicles were mainly designed in terms of the preimpregnation
capacity of polypeptides in CaCO3 particles and particle density in the delivery systems. We
determined drug loading and release in the multilayer films using the fluorescence labeling
method. Although the particle density on multilayer films was almost the same (Figure 3a’c’), the fluorescence intensity of particle-integrated films significantly improved with
increasing incubation time (from 5 to 30 min) of CaCO3 particles in 2 mg mL−1 of PL-FITC
solution, as presented in Figure 3a-c. Plotting the amount of PL-FITC in CaCO3 particles
versus their incubation time revealed that the impregnation achieved saturation with
incubation time of 20 min, and ~3.8 ng per particle of PL was impregnated, as shown in
Figure 3d. This result was further confirmed by the SEM analysis of CaCO3 particles with
fully blocked pores (Figure 1b). Figure 3e-g,e’- g’ shows the assembly of shelled CaCO3
particles on (PL/ PG)5 multilayer films incubated in CaCO3PL-FITC particle suspension with
various times. With increasing incubation time from 10 to 180 min (Figure 3h), the particles
on films exhibited distribution densities of 800, 2490, 8160, 12 300, 14 500, and 15 100 cm
−2, revealing that the incubation time of 120 min was enough to endow saturated particle
assembly in our delivery vehicles. To provide insight into the successful assembly of
preimpregnated capsules, we also performed in situ CLSM observation for our delivery
vehicles before and after CaCO3 template removal (Figure 3i-k); the results indicated that
most impregnated PL polypeptides remained after CaCO3 decomposition. Figure 3l
illustrates the morphology of our developed delivery vehicles of (PL/ PG)5/
capsulePL-FITC/PG/(PL/PG)8, suggesting a uniform distribution of capsules in the PL/PG
multilayer films.

Author Manuscript
3.2.

Multiple Drug-Loading and Release Studies.
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After optimizing the hierarchical structures of multilayer films, we assessed the delivery
capability for multiple drugs of very different properties. Fluorescently labeled BSA and
histone were studied as two model drugs. BSA with isoelectric point (pi) of ~5, a negatively
charged drug model under pH = 7.4, could be easily loaded into L5/CG/L8/CL/L8 delivery
vehicles, which is visualized under CLSM, as shown in Figure 4a-c. To confirm the detailed
loading location, both capsules and BSA were fluorescence labeled, and the results are
shown in Figure S5. The green fluorescent spots (i.e., PL-FITC; Figure S5a-c) overlapped
with the red fluorescent ones (i.e., Alexa Fluor 647- conjugated BSA; Figure S5a’-c’),
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indicating the successful loading of BSA within PL-impregnated capsules in our delivery
vehicles. The L5/CG/L8/CL/L8 films also functioned as delivery vehicles for loading the
positively charged drug model of Alexa Fluor 488-conjugated histone H1 from calf thymus
(pi ~ 11.3), as illustrated in Figure 4d-f. Moreover, BSA and histone loading were both
facilely tunable, for instance, via a simple control of incubation time (Figure 4g,h). With
increasing incubation time from 2 to 20 min, the fluorescence intensity of our drug-loaded
delivery vehicles increased significantly (Figure 4a-c,d-f). Loading of BSA reached a
maximum of ~80 μg cm−2 at 20 min incubation, whereas histone loading showed a higher
value of 100 μg cm−2 at 20 min incubation, as exhibited in Figure 4g,h. Besides the loading
capability after vehicle preparation, it is worth noting that both of these two loading
processes of our delivery vehicles were mostly finished within 10 min, revealing their fast
loading capacity and robust clinical application potential, such as realization of controlled
drug loading just minutes before surgical implantation, which has been rarely reported
previously.22
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We further examined the release profiles of multiple drugs to reveal the tunability and
kinetics of drug release from PL/PG delivery vehicles with different hierarchical structures.
Here, pH was employed as a means of controlling the loading and release of multiple drugs:
loading under a large pH gap above/ below pi of drugs by virtue of the electrostatic
attraction driven from resultant net charges and release under pH similar to pI of drugs due
to disappearance of “binding sites” based on reduced net charges, which was confirmed by
our previous studies.37,49 As demonstrated in Figure 5a,b, an obvious release within 1 day of
BSA and histone was triggered due to pH variation, followed by sustained release behavior,
for delivery vehicles integrated with capsulePL and capsulePG, respectively. However, very
little loading and release of BSA (7 μg cm−2) and of histone (8 μg cm−2) were found in
PL/PG multilayer films without capsules and like-charged capsules. The comparison of
release profiles between vehicles with and without capsulePL/capsulePG suggested that the
delivery process was governed mainly by electrostatic interactions derived from the
impregnated capsules with opposite charges. With an increasing number of PL/PG bilayers
as the outermost layers of the films ranging from 3 to 8 to 13, the “burst effect” of drug
release was significantly weakened, which could be attributed to the shielding effect from
shell-like PL/PG multilayer films. For instance, the release of BSA within the 1st day from
L5/CG/L8/CL/L3 films was 50 μg cm−2, whereas that from L5/CG/L8/CL/L13 films was 32 μg
cm−2, showing a 35% decrease of “burst release” compared with the former one. This result
suggests an effective strategy to tune the drug release profiles for achieving a progressive
release from capsule- based delivery vehicles. L5/CG/L8/CL/L13 delivery vehicles showed a
total release of ~71 μg cm−2 within 14 days (Figure 5a). Similarly, ~48 μg cm−2 of histone
was released from L5/ CG/L13/CL/L8 films within 7 days, and ~85 μg cm−2 was released
within almost 6 weeks. Moreover, compared with L5/ CG/L8/CL/L8 films drug-loaded for 15
min, the capsule-integrated films incubated with less time (5 min) exhibited a similar release
tendency but with a proportional reduction, further confirming the controllable drug-loading
capacity of our delivery vehicles by adjusting the drug incubation time. In addition, the
releases of BSA and histone from L5/CG/L8/CL/ L8 films immersed in SBF were found to be
43 and 36 μg cm−2, respectively, within the 1st day, and reached ~68 μg cm−2 of BSA and
~67 μg cm−2 of histone within 10 days (Figure S6).
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Recently, a promising antimicrobial agent, AgNPs, is emerging as a new treatment option
against a wide array of pathogens.52–54 In this work, we used PVP-capped AgNPs as a
delivery drug to endow our vehicles with the capability of preventing postoperative infection
which may be less likely to induce resistance, a challenge in dental and orthopedic surgeries.
55,56 First, the physicochemical properties of our AgNPs were analyzed for their size
distribution and ζ potential. Over 80% of AgNPs were in the range of 8–25 nm with an
average value of 13.5 nm (Figure 6a), and a normalized three-dimensional (3D) graph (size
vs intensity vs concentration) was also presented (inset of Figure 6a). As illustrated in Figure
6b, the surface ζ potential of AgNPs was determined to be −14.9 ± 0.3 mV, indicating their
loading capacity to capsulePL-based delivery vehicles through electrostatic interactions. By
measuring the absorption spectra at 410 nm, the release profile of AgNP from our delivery
vehicles was also evaluated. As shown in Figure S7a, the delivery vehicle of L5/CG/L8/CL/
L8 film, which was loaded in 0.1 mg mL−1 of AgNP suspension for 40 min, showed a
release of ~18 μg cm−2 AgNP within the 1st day and reached a total release of ~40 μg cm−2
after 2 weeks. To quantitatively characterize the antibacterial activity of our delivery
vehicles encapsulated with AgNPs, we carried out in vitro bacterial assays toward S. aureus
using various delivery vehicles with different hierarchical structures. The obtained S. aureus
killing efficacy is shown in Figure 6c. The antibacterial activities of L23 and L5/CG/L8/CL/L8
films were negligible with a calculated efficacy of ~2%. This result could be attributed to the
disordered topography arising from surface roughness of the polypeptide PL layers, which
was consistent with other studies.9,57 Compared to these two control delivery vehicles, the
L5/CG/L8/CL+AgNPs/L8 films loaded in 0.1 mg mL−1 of AgNP suspension showed an
obvious antibacterial activity with dose-dependent killing efficacy. The AgNP-loaded
vehicles with different incubation time ranging from 5, 20, 40, and 60 min exhibited killing
efficiencies of 26.8, 49.3, 72.5, and 83.1%, respectively, suggesting an effective strategy for
preventing implant infection by loading of AgNPs in our designed capsule-integrated
multilayer films. Also, the successful loading of AgNPs further confirmed the robust
delivery capability of our developed vehicles to deliver multiple drugs with very different
properties, even particles, in a post-preparation loading manner. To compare the efficacy of
AgNPs released from L5/CG/L8/CL+AgNPs/L8 film and in original suspension, we studied the
killing efficacy of AgNP original suspension: these AgNPs exhibited strong antibacterial
activity against S. aureus, displaying killing efficacies of 42.5% at 20 μM and 99.4% at 93
μM in solutions.
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Generally, concern about the toxicity of AgNPs has limited their clinical use.58,59 In this
study, human osteoblast viability using the Trypan blue assay was conducted to determine
the toxicity of various delivery vehicles encapsulated with/without AgNPs and control
AgNP suspensions, as shown in Figure 6d. Excellent viability of osteoblasts (~95%) was
observed using L23 and L5/CG/L8/CL/L8 films without AgNP loading due to their good
biocompatibility from polypeptides. Compared to the 93 μM AgNP suspension, the
decreased concentration (20 μM) led to significantly low toxicity to osteoblast cells with a
viability of 92%. Our delivery vehicles of L5/CG/L8/CL+AgNPs/ L8 films loaded with AgNPs
with different incubation time of 5, 20, 40, and 60 min achieved viabilities of 90, 92, 90, and
85%, respectively, suggesting their low toxicity toward human cells yet with similar S.
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aureus killing efficacy as AgNP suspensions. The phenomenon could be attributed to the
strategy of using delivery vehicles with sustained release capacity rather than a one-time and
high-concentration release which may greatly decrease the toxicity to osteoblasts while keep
an effective dose for killing bacteria, which was consistent with other studies.26,60
3.4.

Bone Regeneration Capacity Evaluation.
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Up to now, although rhBMP-2 presents outstanding regenerative properties for bone
regeneration, the clinical utilization of its delivery system has been associated with severe
side effects due to noncontrolled delivery and nonbiocompatible vehicles.61,62 Here, our
PL/PG-based capsule-integrated multilayer films provided an effective, biocompatible, and
fully resorbable delivery vehicle for a pH-responsive release of rhBMP-2. On the basis of
ELISA tests (Figure S7b), the drug-loaded L5/CG/ L8/CL/L8 films, which were incubated in
4 μg mL−1 of rhBMP- 2 solutions for 20 min, achieved a release of ~20.5 μg cm−2 rhBMP-2
within the 1st day and obtained a total release of ~55 μg cm−2 within 6 weeks, further
demonstrated a robust delivery capacity of our delivery vehicles to achieve a sustained
release. As illustrated in Figure 7a, compared to the uncoated quartz slides, substantially
more osteoblast cells were attached on the slides coated with polypeptide nanofilms. The
PL/PG multilayer films with and without capsules had a similar change of cell density
within the 12 h culture time; meanwhile, capsule-integrated films loaded with rhBMP-2
showed a significant increase in cell density at 4, 8, and 12 h compared to the two control
systems, and their cell density increased with increasing incubation time in rhBMP-2
solution. For example, at 4 h, the cell densities on quartz slides, L23 films, L5/ CG/L8/Cl/L8
films, and L5/CG+bmp/L8/Cl/L8 films incubated in rhBMP-2 solution for 5 and 15 min, were
500, 3500, 4000, 6800, and 8200 cell cm−2, respectively. At 12 h, the cell density on
capsule-integrated films loaded with rhBMP-2 for 15 min achieved 13500 cell cm−2,
indicating a rapid and enhanced cell adhesion by virtue of the combination effect from
hierarchical surface structure and rhBMP-2 stimulation. Figure 7b shows the proliferation of
osteoblast cells on different culture surfaces at 1, 3, and 5 days. The cell proliferation was
significantly enhanced on polypeptide films compared to control quartz slides. For instance,
after 3 days, the cell densities on quartz slides, L23 films, L5/CG/L8/Cl/L8 films,
L5/CG+bmp/L8/Cl/L8 films loaded with rhBMP-2 for 5 and 15 min, were 6000, 16 200, 17 500,
24 200, and 26 500 cell cm−2, respectively. For L23 and L5/CG/L8/Cl/L8 films, cell proliferation
slowed down from 3 to 5 days compared to that from 1 to 3 days. For rhBMP-2-loaded
capsule-integrated vehicles, a rapid and sustained cell growth was observed from 1 to 5 days,
and high cell densities of 28 000 and 34 200 cell cm−2 were obtained at 5 days, respectively,
further confirming the bone regeneration effect from controlled and sustained release of
rhBMP-2 in our capsule-integrated delivery vehicles. Moreover, the percentages of live
osteoblast cells on polypeptide films without rhBMP-2 and control quartz slides were about
the same and were in the range of 70–75% at 1, 3, and 5 days; whereas those of rhBMP-2encapsulated PL/PG delivery vehicles were significantly higher and were in the range of 90–
95% (Figure 7c). This result indicated that, compared to the control quartz sides and PL/PG
films, the encapsulation of rhBMP-2 had shown higher osteoblast cell viability. In addition,
Figure 7d presents osteoblast cell adhesion on various culture surfaces mentioned in Figure
7b,c at 1 day. Obviously, a growing number of cells attached on the culture surfaces ranging
from quartz slides and PL/PG films to capsule-integrated films without and with rhBMP-2
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(Figure 7d-i-v), and better cell spread was achieved on polypeptide films (especially on
rhBMP-2 loaded delivery films) compared to the uncoated quartz slides. The detailed SEM
image showing the firm adhesion of osteoblast cells on polypeptide films is illustrated in
Figure 7d-vi.

4.

CONCLUSIONS
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In summary, we have, for the first time, presented a robust strategy for creating innovative
vehicles assembled by polypeptide capsules and multilayer films to deliver multiple drugs
via the LbL self-assembly technique, for preventing implant-associated infections and
promoting bone regeneration. High, precisely controlled, and postpreparation loading
capacity was achieved via creating polyelectrolyte-impregnated microcapsules functioning
as the main delivery vehicles, whereas on-demand and sustained release in patient-specific
time sequences was further designed by integrating microcapsules into multilayer films.
Four very different drugs including BSA, histone, AgNPs, and rhBMP-2 were successfully
loaded into the capsule-integrated multilayer films at any time post-preparation and
exhibited high and controllable loading (for instance, 80 μg cm−2 of BSA and 100 μg cm−2
of histone) and sustained release profiles (up to 2 weeks or longer). With the robust and
controlled loading and release capacity for multiple drugs driven by the hierarchical nano/
microlevel structures, our designed delivery vehicles achieved a S. aureus killing efficacy of
83% while maintaining an osteoblast viability of >85% using AgNP delivery. Our delivery
vehicles had more than 10-fold cell adhesion capability within 4 h, 5fold cell proliferation
capability within 5 days, and greatly enhanced live cell percentage of >90% with successful
delivery of rhBMP-2. We believe that such delivery vehicles based on capsule-integrated
multilayer films will open up numerous opportunities for a range of orthopedic surgery
applications, such as musculoskeletal trauma, spine diseases, sports injuries, degenerative
diseases, infections, congenital disorders, and so on.
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Figure 1.

SEM images of (a) CaCO3 template particles, (b) CaCO3PL particles, (c) cross-linked
(PL/PG)3.5 nanofilm-shelled CaCO3PL particles, (d) capsulePL, (e) (PL/PG)5 multilayer
nanofilm, (f) shelled CaCO3 particles on (PL/PG)5 film, and (g) capsulePL on (PL/PG)5
nanofilm. AFM images of the zone (h) without and (i) with capsules on capsulePL-integrated
(PL/PG)5 multilayer films.
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Figure 2.

Growth profiles of PL/PG multilayer nanofilms (a) on quartz slides using UV-vis
spectrometry and (b) on silicon wafers using ellipsometry. (c) WCAs of quartz slides
without and with different PL/PG multilayer nanofilms. (d) SEM images of nanoscale
coatings on K-wire after implantation. * p < 0.001 compared to quartz, ^ p < 0.001
compared to (PL/PG)3 5 film, # p < 0.01 compared to (PL/PG)3 film.
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Figure 3.

Author Manuscript

CLSM images of CaCO3PL-FITC particles with different incubation time of (a) 5, (b) 15, and
(c) 30 min in PL-FITC solution, (a’)-(c’) are the corresponding images under transmittance
mode. (d) Impregnation of PL within CaCO3 particles as a function of incubation time in 2
mg mL−1 of PL solution. CLSM image of CaCO3PL FITC particle assembled on multilayer
films with different incubation time of (e) 30, (f) 60, and (g) 120 min in CaCO3 PL-FITC
particle suspension, (e’)-(g’) are the corresponding images under transmittance mode. (h)
CaCO3 particle density on (PL/PG)5 multilayer films as a function of incubation time in
CaCO3 particle suspension (6 × 106 particles mL−1). In situ observation of (PL/ PG)5/
capsulePL-FITC/PG/(PL/PG)8 films CLSM images (i) before and (j) after CaCO3
decomposition under fluorescence mode and (k) is the corresponding image of (j) under
transmittance mode. (l) SEM image of the (PL/PG)5/capsule PL-FITC /PG/(PL/PG)8
multilayer films.
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Figure 4.
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CLSM images of delivery vehicles of L5/CG/L8/CL/L8 films loaded with BSA for (a) 2, (b)
10, and (c) 20 min and loaded with histone for (d) 2, (e) 10, and (f) 20 min. Loading profiles
of (g) BSA and (h) histone with increasing incubation time. BSA and histone are visualized
at (a-c) 647 and (d-f) 488 nm, respectively.
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Figure 5.

Cumulative release profiles of (a) BSA and (b) histone from PL/PG multilayer films with
and without capsulePL or capsulePG and with different loading incubation time. The samples
used in (a) included (a) L5/CG/L8/CL/L3 film, (b) L5/CG/L8/CL/L8 film, (c) L5/CG/L8/CL/L13
film, (d) L5/CG/L8/CL/L8 film incubated in drug solutions for 5 min, (e) L5/CG/L8/CG/Li
film, and (f) L18 film. The samples used in (b) included (a) L5/CG/L3/CL/L8 film, (b) L5/CG/
L8/CL/L8 film, (c) L5/CG/L13/Cl/L8 film, (d) L5/CG/L8/CL/L8 film incubated in drug
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solutions for 5 min, (e) L5/CL/L8/CL/L/8 film, and (f) L18 film. All of the samples were
incubated for 15 min unless otherwise noted.
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Figure 6.

Author Manuscript

(a) Size distribution and (b) ζ potential of PVP-capped AgNPs. Inset is the corresponding
normalized 3D graph (size vs intensity vs concentration). (c) S. aureus killing efficacy and
(d) osteoblast viability of various delivery vehicles with/without AgNP loading and AgNP
suspensions. The samples used in (c) and (d) included (a) L23 film, (b) L5/CG/L8/CL/L8 film,
(c-f) L5/CG/L8/CL+AgNPs/L8 film incubated in Ag suspension for 5, 20, 40, and 60 min,
respectively, (g) 93 μM Ag suspension, and (h) 20 μM Ag suspension. * p < 0.01 compared
to sample (a), ^ p < 0.01 compared to sample (c). # p < 0.01 compared to sample (g). & p <
0.01 compared to sample (f).
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Figure 7.
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(a) Cell density of osteoblast cells on control substrates, substrates with PL/PG multilayer
film, and substrates with PL/PG films incorporated with rhBMP-2 at 1, 2, 4, 8, and 12 h. (b)
Proliferation of osteoblast cells and (c) percentage of living cells on various substrates at 1,
3, and 5 days. The samples used in (a)-(c) included (a) quartz slide, (b) L23 film, (c)
L5/CG/L8/CL/L8 film, (d, e) L5/CG+BMP/L8/CL/L8 films incubated in rhBMP-2 solution for 5
and 15 min, respectively. (d) Images of osteoblast cell adhesion on samples in (b) and (c) at
24 h. (i-v) Correspond to the samples (a)-(e), respectively. (vi) SEM image of osteoblast cell
adhesion. * p < 0.01 compared to quartz, ^ p < 0.01 compared to the same samples cultured
at 1 day.
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Scheme 1. Schematic Diagram Showing the Formation Process of Capsule-Integrated PL/PG
Multilayer Films for Multidrug Delivery Using LbL Self-Assembly Technologya
aThe capsules impregnated with PL or PG polypeptides can function as vehicles for

positively and negatively charged drug loading and release. (1) Self-assembly of (PL/PG)x
multilayer nanofilms; (2) deposition of PG-impregnated CaCO3 particles (CaCO3PG); (3)
self-assembly of PG/(PL/PG)y multilayer nanofilms; (4) deposition of PL-impregnated
CaCO3 particles (CaCO3PL); (5) self-assembly of PG/(PL/PG)z multilayer nanofilms; (6)
formation of capsule-integrated multilayer films by dissolving CaCO3 templates; and (7)
pH-controlled drug loading and release.
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